Scotiabank Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $177.00

Gilead Sciences (NASDAQ:GILD) had its target price raised by research analysts at Scotiabank from $140.00 to $177.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank’s target price would suggest a potential upside of 20.22% from the company’s current price.

Several other analysts have also issued reports on the stock. Royal Bank Of Canada increased their price target on shares of Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a research report on Tuesday, January 20th. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. UBS Group boosted their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Needham & Company LLC lifted their price target on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock a “buy” rating in a report on Wednesday. Twenty-five analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $140.08.

Gilead Sciences Stock Down 2.9%

Gilead Sciences stock opened at $147.23 on Wednesday. The stock has a market cap of $182.67 billion, a P/E ratio of 22.83, a P/E/G ratio of 0.80 and a beta of 0.36. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences has a twelve month low of $93.37 and a twelve month high of $153.13. The company’s 50-day moving average price is $128.39 and its two-hundred day moving average price is $121.53.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the previous year, the company earned $1.90 EPS. The business’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts expect that Gilead Sciences will post 7.95 EPS for the current year.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the completion of the transaction, the chief executive officer directly owned 613,912 shares in the company, valued at $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 319,391 shares of company stock valued at $44,141,101. Company insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Brighton Jones LLC increased its holdings in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth $215,000. Sivia Capital Partners LLC boosted its holdings in shares of Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after acquiring an additional 602 shares during the period. Vest Financial LLC boosted its stake in Gilead Sciences by 39.3% in the 2nd quarter. Vest Financial LLC now owns 14,472 shares of the biopharmaceutical company’s stock worth $1,605,000 after purchasing an additional 4,080 shares during the period. Finally, Cornerstone Wealth Group LLC grew its stake in Gilead Sciences by 20.1% during the second quarter. Cornerstone Wealth Group LLC now owns 2,822 shares of the biopharmaceutical company’s stock valued at $313,000 after acquiring an additional 472 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat: Gilead reported EPS of $1.86 and revenue of ~$7.9B, topping consensus and driven by strong HIV and liver‑disease sales. Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth …
• Positive Sentiment: Dividend raised: Board approved a 3.8% increase to $0.82 quarterly ($0.82 payable Mar 30; ex‑div Mar 13), supporting income investors (yield ~2.2%). Gilead Sciences Announces 3.8-Percent Increase in First Quarter 2026 Dividend
• Positive Sentiment: Pipeline and launches: Management highlighted Yeztugo launch momentum and possible approvals later this year (two cancer therapies plus an additional HIV option), which could drive future growth. Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products
• Neutral Sentiment: Full Q4 call transcript now available for detail on revenue mix and margin drivers — useful for investors digging into product‑level trends. Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analysts’ metric review: Several outlets note Gilead beat top‑ and bottom‑line estimates but some year‑over‑year metrics are mixed — monitor product mix and FX effects in the slides. Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS guidance of $8.45–8.85 and revenue $29.6–30.0B sit at or below consensus (EPS ~8.69; revenue ~30.1B), prompting the after‑hours selloff. Expect near‑term pressure until guidance proves conservative or growth catalysts materialize. Gilead 2026 outlook short of Wall Street view, shares dip

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.